Daicel Corporation
Revised Numerical Targets for Mid-term Strategy “Accelerate 2030”
Partial revision of the mid-term strategy Accelerate 2030's numerical targets. Updated targets for net sales, operating income, EBITDA and ROE for FY2028 and FY2030. Segment-level structural reforms and reorganizations are planned across High Performance Polymers, Materials, Safety, Smart, and Life Science, with adjustments to investment allocation to maintain ROIC. Exchange rate assumptions assume USD/JPY around 150.
Key Figures
- Capital Expenditure: 800 hundred million yen→1,150 hundred million yen (2026→2028)/450 hundred million yen→revised
- Net Sales: 6,950 hundred million yen (FY2026 forecast)→7,750 hundred million yen (FY2030 forecast)
- EBITDA: 1,290 hundred million yen (FY2026 forecast)→1,880 hundred million yen (FY2030 forecast)
AI要約
Mid-term Strategy Review and Investment Policy
The review of Accelerate 2030 re-evaluates growth opportunities centered on Materials and High Performance Polymers, including demand for optical connectors for AI data centers and expanded applications of cellulose acetate. By refining investment amounts, timing and benefits, targets for net sales and profits for FY2028 and FY2030 have been updated. Emphasis is placed on restraining investment in base businesses while improving profitability, and maintaining ROIC across quadrants for next-generation development, growth drivers and transformation.
Financial and Capital Policy Direction
With a focus on maximizing capital efficiency, long-term targets are set at ROE ≥ 17% and ROIC ≥ 12%. The company will prioritize growth investments from cash flows while maintaining balance with shareholder returns. Capital expenditure totals for FY2026–2030 will be adjusted, with a policy to raise DOE to above 5% and total shareholder return ratio to over 60%.
Daicel Corporation
Company overview · Stock price · Financial data · All IR
